Ceftriaxon Navamedic: Uses, Dosage & Side Effects
A third-generation cephalosporin antibiotic administered intravenously for the treatment of serious bacterial infections in adults and children
Ceftriaxon Navamedic (ceftriaxone) is a broad-spectrum, third-generation cephalosporin antibiotic used to treat serious bacterial infections. Administered by intravenous infusion or injection, ceftriaxone is a cornerstone of hospital-based antimicrobial therapy worldwide. It is effective against a wide range of Gram-positive and Gram-negative bacteria and has the advantage of a long elimination half-life (approximately 6–9 hours), allowing convenient once-daily dosing. Listed on the WHO Model List of Essential Medicines, ceftriaxone is used to treat meningitis, pneumonia, sepsis, urinary tract infections, bone and joint infections, and many other serious infections. It requires a prescription and is typically prepared and administered by healthcare professionals in a clinical setting.
Quick Facts: Ceftriaxon Navamedic
Key Takeaways
- Ceftriaxon Navamedic (ceftriaxone) is a third-generation cephalosporin antibiotic administered intravenously or intramuscularly; it is on the WHO Model List of Essential Medicines and is one of the most important hospital antibiotics globally.
- Do not use ceftriaxone if you have a history of severe immediate allergic reaction (anaphylaxis) to penicillin or other beta-lactam antibiotics; it must never be mixed with or given simultaneously with calcium-containing intravenous solutions.
- Its long half-life of 6–9 hours allows convenient once-daily dosing for most indications, making it particularly practical for outpatient parenteral antibiotic therapy (OPAT) programs.
- Common side effects include diarrhea, changes in blood cell counts, rash, and elevated liver enzymes; serious but rare side effects include severe allergic reactions, pseudomembranous colitis, and biliary or renal precipitates.
- Ceftriaxone is contraindicated in premature neonates and in full-term neonates (up to 28 days old) with jaundice, low albumin, or acidosis, or who require calcium-containing IV products.
What Is Ceftriaxon Navamedic and What Is It Used For?
Ceftriaxone is a semi-synthetic, broad-spectrum, third-generation cephalosporin antibiotic that has been in clinical use since the early 1980s. It was developed by Hoffmann-La Roche and originally marketed under the brand name Rocephin. Ceftriaxon Navamedic is a generic formulation manufactured by ANFARM Hellas and ACS Dobfar, marketed by Navamedic ASA. It is supplied as a sterile white to off-white crystalline powder that is reconstituted into a solution for intravenous infusion or injection before administration.
The medication works through a bactericidal mechanism characteristic of all beta-lactam antibiotics. Ceftriaxone binds with high affinity to penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cells. These PBPs are transpeptidase enzymes essential for the final cross-linking step in peptidoglycan biosynthesis, which provides structural integrity to the bacterial cell wall. By inhibiting these enzymes, ceftriaxone prevents the formation of a functional cell wall. As the bacterium continues to grow and divide without adequate cell wall support, osmotic pressure leads to cell lysis and death. Ceftriaxone is notable for its exceptional stability against hydrolysis by most clinically important beta-lactamases, including many extended-spectrum beta-lactamases (ESBLs), although it is susceptible to some carbapenemases and AmpC beta-lactamases.
One of the most distinctive pharmacokinetic properties of ceftriaxone is its unusually long elimination half-life of approximately 5.8 to 8.7 hours in adults with normal renal and hepatic function. This is considerably longer than most other cephalosporins (which typically have half-lives of 1–2 hours) and is primarily due to its high degree of protein binding (85–95%, mainly to serum albumin). This extended half-life is clinically significant because it permits once-daily dosing for most indications, improving patient convenience and compliance and making ceftriaxone particularly suitable for outpatient parenteral antibiotic therapy (OPAT) programs where patients receive intravenous antibiotics outside of the hospital setting.
Ceftriaxone achieves therapeutic concentrations in virtually all body tissues and fluids, including the cerebrospinal fluid (CSF) when the meninges are inflamed. This excellent CSF penetration is a critical advantage that makes ceftriaxone a first-line treatment for bacterial meningitis. The drug is eliminated by both renal (approximately 33–67% as unchanged drug in urine) and biliary (approximately 33–67% in bile) routes, with the relative contribution depending on the dose and the patient’s renal function. This dual elimination pathway means that dose adjustment is generally not required in patients with renal impairment alone or hepatic impairment alone, though monitoring is recommended in patients with combined severe renal and hepatic dysfunction.
Ceftriaxon Navamedic is indicated for the treatment of the following infections when caused by susceptible organisms:
- Bacterial meningitis: First-line empirical treatment for community-acquired bacterial meningitis in both adults and children, effective against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.
- Community-acquired pneumonia: Moderate to severe cases requiring hospitalization, typically in combination with a macrolide or respiratory fluoroquinolone for atypical coverage.
- Hospital-acquired pneumonia: As part of combination therapy regimens based on local resistance patterns.
- Acute otitis media (middle ear infection): Reserved for cases that fail oral antibiotic therapy or for patients unable to take oral medications.
- Intra-abdominal infections: Peritonitis and other abdominal infections, usually in combination with metronidazole for anaerobic coverage.
- Complicated urinary tract infections and pyelonephritis: Including severe cases requiring intravenous therapy.
- Bone and joint infections: Osteomyelitis and septic arthritis, often as part of a prolonged treatment course.
- Skin and soft tissue infections: Complicated cellulitis, wound infections, and other serious soft tissue infections.
- Bloodstream infections (sepsis/bacteremia): Both as empirical therapy and as directed therapy once the causative organism is identified.
- Endocarditis: Infective endocarditis caused by susceptible organisms, typically as part of combination therapy.
- Gonorrhea and syphilis: Ceftriaxone is the recommended first-line treatment for uncomplicated gonorrhea worldwide and is used for neurosyphilis.
- Lyme disease (Lyme borreliosis): Stage II and III disease, including Lyme neuroborreliosis and Lyme arthritis, in adults and children from 15 days of age.
- Febrile neutropenia: Empirical therapy in patients with low white blood cell counts and fever suspected to be caused by bacterial infection.
- Surgical prophylaxis: Prevention of postoperative infections in certain surgical procedures.
Ceftriaxone is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its critical importance in global healthcare. Under the WHO AWaRe (Access, Watch, Reserve) classification system, ceftriaxone is classified as a Watch antibiotic, indicating that while it is an essential medicine, its use should be carefully monitored to preserve its effectiveness and minimize the development of antimicrobial resistance. Healthcare professionals are encouraged to use ceftriaxone only when first-line Access antibiotics are not appropriate.
Ceftriaxone should only be used for confirmed or strongly suspected bacterial infections. Inappropriate use of broad-spectrum antibiotics like ceftriaxone contributes to the global crisis of antimicrobial resistance, which the WHO has identified as one of the top 10 global public health threats. Broad-spectrum cephalosporins are particularly implicated in the selection of extended-spectrum beta-lactamase (ESBL)-producing organisms and Clostridioides difficile infection. Always follow local antimicrobial stewardship guidelines and de-escalate to narrower-spectrum agents when culture and sensitivity results become available.
What Should You Know Before Receiving Ceftriaxon Navamedic?
Contraindications
There are specific situations where ceftriaxone must not be used. Understanding these absolute contraindications is critical for patient safety, particularly given that ceftriaxone is administered parenterally, which means adverse reactions may develop rapidly.
- Cephalosporin allergy: Do not use if you are allergic to ceftriaxone or any other cephalosporin antibiotic, or to any of the inactive ingredients in the formulation.
- Severe penicillin or beta-lactam allergy: Do not use if you have ever had a sudden or severe allergic reaction to penicillin or any similar antibiotic (cephalosporins, carbapenems, or monobactams). Symptoms of severe immediate allergy include sudden swelling of the throat or face making it difficult to breathe or swallow, sudden swelling of hands, feet, or ankles, chest pain, and severe rash that develops rapidly. Note that the cross-reactivity between penicillins and third-generation cephalosporins is estimated to be low (1–2%), so patients with mild, non-immediate penicillin reactions can often safely receive ceftriaxone under medical supervision.
- Lidocaine allergy (for IM use only): If ceftriaxone is to be administered by intramuscular injection with lidocaine as a diluent, it must not be given to patients with a known allergy to lidocaine or other amide-type local anesthetics.
- Premature neonates: Ceftriaxone is contraindicated in premature infants up to a corrected gestational age of 41 weeks (gestational age plus chronological age).
- Full-term neonates (0–28 days): Ceftriaxone must not be used in neonates who have jaundice (hyperbilirubinemia), low albumin levels (hypoalbuminemia), or acidosis, as these conditions increase the risk of ceftriaxone displacing bilirubin from albumin binding sites, potentially leading to bilirubin encephalopathy (kernicterus). It must also not be given to neonates who are receiving or expected to receive calcium-containing IV products.
Ceftriaxone must never be mixed with or administered simultaneously with calcium-containing intravenous solutions, including parenteral nutrition solutions containing calcium. In neonates, fatal cases of ceftriaxone-calcium precipitates in the lungs and kidneys have been reported. In patients older than 28 days (including adults), ceftriaxone and calcium-containing IV solutions may be given sequentially provided the infusion lines are thoroughly flushed with a compatible fluid between administrations. Ceftriaxone must not be reconstituted or diluted with Ringer’s solution, Hartmann’s solution, or any other calcium-containing diluent.
Warnings and Precautions
Inform your doctor, pharmacist, or nurse before receiving ceftriaxone if any of the following apply to you:
- History of severe skin reactions: If you have ever experienced a combination of symptoms including widespread skin rash, redness, blistering of the lips, eyes, or mouth, peeling skin, high fever, flu-like symptoms, elevated liver enzymes, or enlarged lymph nodes, these may be signs of serious cutaneous adverse reactions (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome). These conditions require immediate medical attention and discontinuation of ceftriaxone.
- Recent or upcoming calcium-containing products: Inform your doctor about any calcium-containing products you have recently received or are expected to receive intravenously.
- Previous antibiotic-associated diarrhea: If you have previously developed diarrhea while taking an antibiotic, or if you have ever had problems with your intestines, particularly colitis (inflammation of the colon). Broad-spectrum antibiotics including ceftriaxone can cause Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to life-threatening pseudomembranous colitis.
- Liver or kidney disease: Ceftriaxone is eliminated by both hepatic and renal routes. In patients with combined severe hepatic and renal impairment, dose reduction and monitoring of drug levels may be necessary. In patients with renal impairment alone or hepatic impairment alone, dose adjustment is generally not required, but regular monitoring is advisable.
- Gallstones or kidney stones: Ceftriaxone can form precipitates in the gallbladder (ceftriaxone-calcium salt precipitates, sometimes referred to as “biliary sludge”) and in the kidneys. These precipitates may cause symptoms mimicking acute cholecystitis or renal colic and are usually reversible upon discontinuation of treatment.
- Hemolytic anemia: Immune-mediated hemolytic anemia has been reported with ceftriaxone. If you develop anemia during treatment, the diagnosis of cephalosporin-associated anemia should be considered and the drug discontinued until the cause is established.
- Sodium-controlled diet: Ceftriaxon Navamedic contains 82.8 mg of sodium per gram of ceftriaxone, equivalent to approximately 4% of the WHO-recommended maximum daily sodium intake for an adult. This should be taken into account in patients on sodium-restricted diets.
Ceftriaxone may affect the results of certain laboratory tests. It can cause false-positive reactions in non-enzymatic urine glucose tests (copper-reduction methods). If you need to test your urine for glucose, use enzyme-based (glucose oxidase) methods instead. Ceftriaxone may also cause a false-positive Coombs test, which is a blood test used to detect antibodies against red blood cells. Some blood glucose monitors may give incorrect readings during ceftriaxone treatment; check the instructions for your monitor and consult your healthcare professional if needed.
Pregnancy and Breastfeeding
Ceftriaxone crosses the placental barrier and is excreted in breast milk in low concentrations. If you are pregnant, think you may be pregnant, or are breastfeeding, tell your doctor before receiving this medicine. Your doctor will carefully weigh the benefit of treating you with ceftriaxone against the potential risk to your baby.
Animal reproduction studies with ceftriaxone have not revealed evidence of teratogenicity (harm to the developing fetus), embryotoxicity, or adverse effects on fertility. However, controlled studies in pregnant women are limited. Ceftriaxone is generally considered acceptable for use in pregnancy when the clinical situation warrants it, and it is recommended by major guidelines (including the Infectious Diseases Society of America and the World Health Organization) for the treatment of serious infections in pregnant women, including gonorrhea, syphilis, and Lyme disease.
Ceftriaxone is excreted in breast milk at low concentrations (approximately 3–4% of maternal serum levels). While this amount is generally considered too small to have a significant clinical effect on the nursing infant, there is a theoretical risk of sensitization (development of allergy) and alteration of bowel flora, which could cause diarrhea or candidiasis (thrush) in the breastfed infant. If your infant develops diarrhea, oral thrush, or skin rash during your treatment, consult your doctor.
Driving and Operating Machinery
Ceftriaxone can occasionally cause dizziness. If you experience dizziness or any other symptom that could impair your ability to concentrate, do not drive a vehicle or operate machinery until the symptoms have resolved. You are responsible for assessing whether you are fit to drive or perform tasks requiring alertness. Discuss with your doctor or pharmacist if you are unsure.
How Does Ceftriaxon Navamedic Interact with Other Drugs?
Ceftriaxone has several clinically important drug interactions that must be managed carefully, particularly in the hospital setting where patients may be receiving multiple intravenous medications simultaneously. Always inform your doctor, pharmacist, or nurse about all prescription and over-the-counter medications, vitamins, herbal remedies, and dietary supplements you are taking or have recently taken.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Calcium-containing IV solutions | Ceftriaxone forms insoluble ceftriaxone-calcium precipitates that can deposit in the lungs, kidneys, and gallbladder, potentially causing fatal organ damage, particularly in neonates | Never mix or administer simultaneously. In patients over 28 days old, sequential infusion is acceptable with thorough line flushing between administrations. Avoid Ringer’s and Hartmann’s solution entirely. |
| Aminoglycoside antibiotics | Aminoglycosides (e.g., gentamicin, amikacin, tobramycin) are physically incompatible with ceftriaxone in the same solution, forming a precipitate. Additionally, concurrent use may increase the risk of nephrotoxicity. | Never mix in the same syringe or IV bag. Administer at different sites or at different times. May be used in combination for synergistic bactericidal effect (e.g., endocarditis) if given separately. Monitor renal function closely. |
| Chloramphenicol | Chloramphenicol is a bacteriostatic antibiotic that may antagonize the bactericidal action of ceftriaxone, as beta-lactams require actively dividing bacteria to exert their cell wall-disrupting effect | Avoid concurrent use where possible. If combination therapy is required, consult an infectious disease specialist for guidance on optimal dosing and timing. |
| Warfarin and oral anticoagulants | Ceftriaxone may enhance the anticoagulant effect of warfarin and other vitamin K antagonists by suppressing gut bacteria that produce vitamin K, or by affecting hepatic metabolism. The INR may increase significantly. | Monitor INR frequently (at least every 2–3 days) during ceftriaxone treatment and for at least one week after discontinuation. Warfarin dose reduction may be necessary. Report any unusual bleeding or bruising. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Oral contraceptives | Broad-spectrum antibiotics may theoretically reduce the efficacy of hormonal contraceptives by disrupting gut flora involved in enterohepatic recirculation of estrogen, though clinical evidence for this with ceftriaxone is limited | Use additional barrier contraception during treatment and for 7 days after the last dose as a precautionary measure, particularly if experiencing vomiting or diarrhea. |
| Loop diuretics (e.g., furosemide) | High-dose loop diuretics used concurrently with cephalosporins may theoretically increase the risk of nephrotoxicity, though this has not been well documented with ceftriaxone specifically | Monitor renal function (serum creatinine, urine output) regularly when high-dose loop diuretics are used concurrently with ceftriaxone. |
| Probenecid | Unlike many other cephalosporins, ceftriaxone clearance is not significantly affected by probenecid because of its substantial biliary elimination pathway | No dose adjustment of ceftriaxone is required when used concurrently with probenecid. This is a notable difference from other beta-lactam antibiotics. |
Solutions containing ceftriaxone must not be mixed with or added to other medications. In particular, diluents containing calcium (Ringer’s solution, Hartmann’s solution) must never be used to reconstitute or dilute ceftriaxone. Compatible diluents include sodium chloride 0.9% (normal saline), glucose 5%, and glucose 12%. Ceftriaxone and other antibiotics should always be administered separately.
What Is the Correct Dosage of Ceftriaxon Navamedic?
Ceftriaxon Navamedic is always prepared and administered by a doctor, pharmacist, or nurse. It can be given as an intravenous (IV) infusion (drip), as a slow intravenous injection directly into a vein, or as a deep intramuscular (IM) injection. The 2 g formulation is specifically designed for intravenous infusion use. Your doctor will determine the correct dose based on the type and severity of your infection, your weight and age, how well your kidneys and liver are functioning, and whether you are taking any other antibiotics.
Adults, Elderly, and Children 12 Years and Older (weighing 50 kg or more)
Standard Treatment
1–2 g once daily, depending on the severity and type of infection. For severe infections, the dose may be increased up to 4 g once daily. If the daily dose exceeds 2 g, it may be administered as a single dose or divided into two separate doses.
| Indication | Dose | Duration |
|---|---|---|
| Standard infections | 1–2 g once daily | Varies by infection |
| Severe infections | Up to 4 g once daily | As clinically indicated |
| Bacterial meningitis | Up to 4 g once daily | 4–7 days (organism-dependent) |
| Lyme disease (Stage II/III) | 50 mg/kg (max 2 g) once daily | 14 days |
| Uncomplicated gonorrhea | 500 mg single IM dose | Single dose |
| Surgical prophylaxis | 2 g as a single dose | 30–90 min before incision |
Children (15 Days to 12 Years, Weighing Less Than 50 kg)
Pediatric Dosing
50–80 mg/kg of body weight once daily, depending on the severity and type of infection. For severe infections, the dose may be increased up to 100 mg/kg/day, to a maximum of 4 g daily. If the daily dose exceeds 2 g, it may be given as a single dose or divided into two doses. Children weighing 50 kg or more should receive the standard adult dose.
| Indication | Dose | Duration |
|---|---|---|
| Standard infections | 50–80 mg/kg once daily | Varies by infection |
| Severe infections | Up to 100 mg/kg/day (max 4 g) | As clinically indicated |
| Bacterial meningitis | Initial 100 mg/kg (max 4 g) | 4–7 days (organism-dependent) |
| Lyme disease (Stage II/III) | 50 mg/kg (max 2 g) once daily | 14 days |
Neonates (0–14 Days)
Neonatal Dosing
20–50 mg/kg of body weight once daily, depending on the severity and type of infection. The maximum daily dose must not exceed 50 mg/kg. Neonates require special caution with ceftriaxone due to the risk of bilirubin displacement and the contraindication with calcium-containing products.
Patients with Liver or Kidney Problems
In patients with renal impairment alone, no dose adjustment is necessary provided hepatic function is normal, because ceftriaxone has a significant biliary elimination pathway. Similarly, in patients with hepatic impairment alone, no dose adjustment is required as long as renal function is normal. However, in patients with combined severe hepatic and renal impairment, the daily dose should not exceed 2 g, and plasma drug concentrations should be monitored regularly. Ceftriaxone is not removed by hemodialysis or peritoneal dialysis, so no supplemental dosing is needed after dialysis sessions.
Administration
For intravenous infusion, the powder is dissolved in a calcium-free infusion solution (e.g., sodium chloride 0.9%, glucose 5%, or glucose 12%) and infused over at least 30 minutes. For slow intravenous injection, the powder is dissolved in sterile water for injection and injected over 5 minutes. For intramuscular injection (1 g formulation only), the powder is dissolved in 1% lidocaine hydrochloride solution and injected deeply into a large muscle. Intramuscular doses exceeding 1 g should be divided and injected into more than one site.
Missed Dose
If you miss a scheduled dose, it should be given as soon as possible. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not receive a double dose to make up for a missed one. Since ceftriaxone is typically administered by healthcare professionals in a clinical setting, missed doses are uncommon.
Overdose
In the event of accidental overdose, symptoms may include nausea, vomiting, and diarrhea. Treatment is supportive and symptomatic. Ceftriaxone is not effectively removed by hemodialysis or peritoneal dialysis. Contact your local poison control center or emergency services immediately if overdose is suspected.
Do not stop receiving ceftriaxone unless your doctor tells you to, even if you begin to feel better. Stopping treatment too early can allow the infection to return and may contribute to the development of antibiotic-resistant bacteria. Your doctor will determine the appropriate duration of treatment based on the type and severity of your infection and your clinical response.
What Are the Side Effects of Ceftriaxon Navamedic?
Like all medicines, ceftriaxone can cause side effects, although not everyone experiences them. The frequency categories below are based on clinical trial data and post-marketing surveillance reports. If you experience any unusual symptoms during or after treatment, inform your healthcare team immediately.
Contact your doctor or emergency services immediately if you experience: sudden swelling of the face, throat, lips, or mouth; difficulty breathing or swallowing; sudden swelling of hands, feet, or ankles; severe chest pain; severe skin rash developing rapidly with blistering or peeling; high fever with widespread rash; or severe, bloody, or persistent diarrhea.
Common
May affect up to 1 in 10 people
- Changes in white blood cell counts (decreased leukocytes, increased eosinophils)
- Decreased platelet count (thrombocytopenia)
- Loose stools or diarrhea
- Changes in liver function test results (elevated transaminases)
- Skin rash
Uncommon
May affect up to 1 in 100 people
- Fungal infections (e.g., oral or vaginal candidiasis/thrush)
- Decreased white blood cell count (granulocytopenia)
- Decreased red blood cell count (anemia)
- Blood clotting problems (easy bruising, joint pain and swelling)
- Headache
- Dizziness
- Nausea or vomiting
- Itching (pruritus)
- Pain or burning at the injection or infusion site
- Fever (pyrexia)
- Abnormal kidney function tests (elevated creatinine)
Rare
May affect up to 1 in 1,000 people
- Inflammation of the colon (colitis) with diarrhea containing blood and mucus, abdominal pain, and fever
- Difficulty breathing (bronchospasm)
- Raised, itchy rash (urticaria/hives) that may cover large areas of the body, with swelling
- Blood or sugar in the urine
- Edema (fluid retention)
- Chills
Frequency Not Known
Cannot be estimated from available data
- Severe allergic reactions (anaphylaxis) with sudden swelling, breathing difficulty, and potential cardiac involvement (Kounis syndrome)
- Severe skin reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), DRESS syndrome
- Secondary infection with resistant organisms
- Hemolytic anemia (destruction of red blood cells)
- Severe decrease in white blood cells (agranulocytosis)
- Seizures and convulsions
- Vertigo (spinning sensation)
- Pancreatitis (inflammation of the pancreas with severe abdominal pain radiating to the back)
- Stomatitis (inflammation of the mouth lining) and glossitis (inflammation of the tongue)
- Gallbladder and liver problems (pain, nausea, jaundice, dark urine, pale stools)
- Kernicterus (bilirubin encephalopathy) in neonates with severe jaundice
- Kidney problems from ceftriaxone-calcium precipitates (pain on urination, reduced urine output)
- Jarisch-Herxheimer reaction (fever, chills, headache, muscle pain, and rash after starting treatment for spirochetal infections such as Lyme disease)
- False-positive Coombs test and false-positive galactosemia screening test
- Interference with certain blood glucose monitors
Prolonged treatment with ceftriaxone, particularly in elderly patients with serious kidney or neurological conditions, may rarely cause decreased consciousness, abnormal involuntary movements, agitation, and seizures. If you experience any of these symptoms, inform your doctor immediately.
Reporting suspected side effects after a medicine has been authorized is important. It allows continued monitoring of the medicine’s benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance agency.
How Should You Store Ceftriaxon Navamedic?
Ceftriaxon Navamedic in its dry powder form does not require special temperature conditions. However, it should be stored in the original packaging to protect it from light, as ceftriaxone is photosensitive and may degrade when exposed to light for prolonged periods.
Once the powder has been reconstituted into a solution for injection or infusion, the product should ideally be used immediately. If not used immediately, chemical and physical in-use stability has been demonstrated for up to 6 hours at room temperature (25°C) and for up to 24 hours under refrigeration (2–8°C). From a microbiological standpoint, the prepared solution should be used as soon as possible after reconstitution.
Keep this medicine out of the sight and reach of children. Do not use after the expiry date stated on the label and carton. The expiry date refers to the last day of the stated month. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to properly dispose of medicines you no longer need. These measures help to protect the environment.
What Does Ceftriaxon Navamedic Contain?
Each vial of Ceftriaxon Navamedic contains:
- Active substance: Ceftriaxone 1 g or 2 g (as ceftriaxone disodium hemiheptahydrate). The salt form (disodium hemiheptahydrate) ensures stability and solubility when reconstituted.
- Appearance: White to off-white crystalline powder supplied in a glass injection vial. When reconstituted, the solution is colorless to slightly yellow due to the active substance.
- Packaging: The 1 g formulation is available in packs of 10 vials. The 2 g formulation is available in packs of 1, 5, or 10 vials (not all pack sizes may be marketed in every country).
- Sodium content: Each gram of ceftriaxone contains approximately 82.8 mg of sodium (3.6 mmol), equivalent to about 4% of the WHO-recommended maximum daily sodium intake for adults (2 g sodium/day). At the maximum adult dose of 4 g daily, sodium intake from ceftriaxone alone would be approximately 331 mg (16.5% of the recommended maximum).
The solution should be inspected visually before use. Only clear solutions without visible particles should be administered. If the reconstituted solution appears cloudy or contains particulate matter, it should be discarded.
Frequently Asked Questions About Ceftriaxon Navamedic
Ceftriaxone (Ceftriaxon Navamedic) is a third-generation cephalosporin antibiotic used to treat serious bacterial infections. Common uses include bacterial meningitis, pneumonia, urinary tract and kidney infections, intra-abdominal infections (peritonitis), bone and joint infections, skin and soft tissue infections, bloodstream infections (sepsis), endocarditis, gonorrhea, syphilis, and Lyme disease. It is also used for surgical prophylaxis and in febrile neutropenia. It is a hospital-use medication given by injection or infusion.
Ceftriaxone is administered parenterally, meaning it is given by injection or infusion rather than taken orally. It can be given as an intravenous (IV) infusion over at least 30 minutes, as a slow IV injection over 5 minutes, or as a deep intramuscular (IM) injection. The 2 g formulation (Ceftriaxon Navamedic 2 g) is specifically designed for IV infusion. It is always prepared and administered by a healthcare professional in a hospital or clinical setting.
People with a history of mild, non-severe penicillin allergy can often safely receive ceftriaxone, as the cross-reactivity rate between penicillins and third-generation cephalosporins is very low (estimated at 1–2%). However, if you have ever had a severe or immediate allergic reaction to penicillin (such as anaphylaxis, severe skin reactions, or swelling of the face and throat), ceftriaxone must not be used. Always inform your doctor about any previous allergic reactions to antibiotics before receiving treatment.
Ceftriaxone must never be mixed with or administered simultaneously with calcium-containing intravenous solutions (such as Ringer’s solution or Hartmann’s solution). This is because ceftriaxone can form insoluble ceftriaxone-calcium precipitates, which have caused fatal reactions in neonates due to precipitation in the lungs and kidneys. In adults and older children, ceftriaxone and calcium-containing IV solutions may be given sequentially if the infusion lines are thoroughly flushed between administrations with a compatible solution.
The most common side effects of ceftriaxone (affecting up to 1 in 10 people) include diarrhea and loose stools, changes in white blood cell counts (leukopenia, eosinophilia), decreased platelet count (thrombocytopenia), skin rash, and changes in liver function tests (elevated transaminases). Less common side effects include fungal infections (candidiasis), headache, dizziness, nausea, vomiting, itching, and pain or inflammation at the injection site. Serious but rare side effects include severe allergic reactions, pseudomembranous colitis, and gallbladder or kidney precipitates.
The duration of ceftriaxone treatment depends on the type and severity of infection. For uncomplicated infections, treatment typically lasts 4–14 days. For bacterial meningitis caused by N. meningitidis, treatment is usually 4 days; for H. influenzae, 6 days; and for S. pneumoniae, 7 days. Lyme disease (stage II and III) is treated for 14 days. Surgical prophylaxis involves a single dose. Your doctor will determine the appropriate treatment duration based on your specific condition and clinical response to therapy.
References
- 1 World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Available from: who.int/publications
- 2 European Medicines Agency (EMA). Ceftriaxone – Summary of Product Characteristics. Amsterdam: EMA; 2024. Available from: ema.europa.eu
- 3 U.S. Food and Drug Administration (FDA). Rocephin (ceftriaxone sodium) – Prescribing Information. Silver Spring, MD: FDA; 2023.
- 4 British National Formulary (BNF). Ceftriaxone Monograph. London: National Institute for Health and Care Excellence (NICE); 2024. Available from: bnf.nice.org.uk
- 5 Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. Clinical Infectious Diseases. 2004;39(9):1267–1284. doi:10.1086/425368
- 6 Patel IH, Chen S, Parsonnet M, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrobial Agents and Chemotherapy. 1981;20(5):634–641. doi:10.1128/AAC.20.5.634
- 7 World Health Organization (WHO). AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use. Geneva: WHO; 2023. Available from: who.int/publications
- 8 Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1–187. doi:10.15585/mmwr.rr7004a1
- 9 Wormser GP, Dattwyler RJ, Shapiro ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2006;43(9):1089–1134. doi:10.1086/508667
- 10 Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical Infectious Diseases. 2011;53(7):e25–e76. doi:10.1093/cid/cir531
About Our Medical Editorial Team
This article has been written and reviewed by our medical editorial team, which includes licensed specialist physicians in clinical pharmacology, infectious disease, and internal medicine. All content is based on the latest international guidelines and peer-reviewed research, following the GRADE evidence framework. Our team has no commercial affiliations and receives no pharmaceutical industry funding.
All medical claims are supported by Level 1A evidence from systematic reviews, meta-analyses, and international clinical practice guidelines (WHO, EMA, FDA, BNF, IDSA).
This article is reviewed and updated regularly to reflect the latest research findings, guideline updates, and safety information. Last reviewed: May 10, 2026.